studies

breast cancer (BC), lapatinib vs. TKI anti HER1/EGFR and HER2/neu, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsEGF104900, 2010 (REV) 1.35 [1.04; 1.75] 1.35[1.04; 1.75]EGF104900, 2010 (REV)10%291NAnot evaluable progression or deaths (PFS)detailed resultsEGF104900, 2010 (REV) 1.35 [1.07; 1.71] 1.35[1.07; 1.71]EGF104900, 2010 (REV)10%296NAnot evaluable objective responses (ORR)detailed resultsEGF104900, 2010 (REV) 0.64 [0.28; 1.48] 0.64[0.28; 1.48]EGF104900, 2010 (REV)10%296NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-07-01 17:59 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 64,370,336,147,145,355,337,146,317,4,319,144,356,351,357,352,354,353,358,359,324,142,305,306,98,96,269,60,143,270,140,240,3 - treatments: 421

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons